Suppr超能文献

靶向蛋白降解优于抑制的优势:以 RTK 为例。

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.

机构信息

Department of Molecular, Cellular, and Developmental Biology, Yale University, 219 Prospect Street, New Haven, CT, USA.

Arvinas, LLC, 5 Science Park, New Haven, CT, USA.

出版信息

Cell Chem Biol. 2018 Jan 18;25(1):67-77.e3. doi: 10.1016/j.chembiol.2017.09.009. Epub 2017 Nov 9.

Abstract

Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degradation. The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degradation over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degradation leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors. Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degradation using the PROTAC technology and outline the advantages of this degradation-based approach.

摘要

在过去的二十年中,蛋白酶体靶向嵌合体(PROTAC)技术已经成为一种强大的工具,可用于靶向降解内源性蛋白质。在此,我们描述了针对受体酪氨酸激酶的 PROTAC 的开发,这是一个尚未针对诱导蛋白降解进行靶向的蛋白质家族。使用 VHL 招募的 PROTAC 针对该蛋白家族进行研究,揭示了降解相对于单独抑制的几个优势:完全功能的、靶向降解的 PROTAC 与含有失活 E3 连接酶招募配体的靶向抑制变体的直接比较表明,降解导致更有效的细胞增殖抑制和更持久和持续的下游信号转导反应,从而解决了许多受体酪氨酸激酶抑制剂所面临的激酶组重排挑战。综上所述,这些发现证明了使用 PROTAC 技术靶向受体酪氨酸激酶进行降解的能力,并概述了这种基于降解的方法的优势。

相似文献

1
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.靶向蛋白降解优于抑制的优势:以 RTK 为例。
Cell Chem Biol. 2018 Jan 18;25(1):67-77.e3. doi: 10.1016/j.chembiol.2017.09.009. Epub 2017 Nov 9.
2
Small-molecule PROTACs: novel agents for cancer therapy.小分子 PROTACs:癌症治疗的新型药物。
Future Med Chem. 2020 May;12(10):915-938. doi: 10.4155/fmc-2019-0340. Epub 2020 Apr 9.
6
The Present and Future of Novel Protein Degradation Technology.新型蛋白降解技术的现状与未来。
Curr Top Med Chem. 2019;19(20):1784-1788. doi: 10.2174/1568026619666191011162955.
8
Cancer Selective Target Degradation by Folate-Caged PROTACs.叶酸笼 PROTAC 对癌症的选择性靶向降解。
J Am Chem Soc. 2021 May 19;143(19):7380-7387. doi: 10.1021/jacs.1c00451. Epub 2021 May 10.

引用本文的文献

3
FDA-approved kinase inhibitors in PROTAC design, development and synthesis.FDA批准的用于PROTAC设计、开发和合成的激酶抑制剂。
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2542357. doi: 10.1080/14756366.2025.2542357. Epub 2025 Aug 12.
8
Methods to accelerate PROTAC drug discovery.加速PROTAC药物发现的方法。
Biochem J. 2025 Jun 25;482(13):BCJ20243018. doi: 10.1042/BCJ20243018.

本文引用的文献

9
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.肺癌中MET外显子14改变:外显子跳跃延长半衰期
Clin Cancer Res. 2016 Jun 15;22(12):2832-4. doi: 10.1158/1078-0432.CCR-16-0229. Epub 2016 Mar 23.
10
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.用于降解致癌性BCR-ABL的模块化PROTAC设计
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. doi: 10.1002/anie.201507634. Epub 2015 Nov 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验